Company / Shareholders' Equity
TG Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$648.0M
FY2025
5-year range
$58.6M / $648.0M
FY2021-FY2025
Trend
+191.4%
vs FY2024
Sector context
#70 of 213
Health Care
What the data says
At $648M, TG Therapeutics, Inc.'s shareholders' equity ranks #70 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $59M in FY2022 to $648M in FY2025.
Based on SEC 10-K filings.
$648M in FY2025 with a 5-year CAGR of +4.5%.
Improved from $161M to $648M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +122.8%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Sector benchmark
#70 of 213 in Health CareTop 33% of 213This company $648.0M Sector average $2.5B
▼
-74.6% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +4.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 191.4% year-over-year.
- Ranks #70 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $648.0M | +191.4% |
| FY2024 | $222.4M | +38.5% |
| FY2023 | $160.5M | +174.0% |
| FY2022 | $58.6M | -75.3% |
| FY2021 | $237.2M | -54.3% |
| FY2020 | $519.4M | +675.2% |
| FY2019 | $67.0M | +178.7% |
| FY2018 | $24.0M | -64.1% |
| FY2017 | $67.0M | +86.8% |
| FY2016 | $35.9M | -64.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026